Refractory dermatomyositis responsive to anifrolumab

Abstract

Dermatomyositis (DM) is a connective tissue disorder with dermatologic and/or extracutaneous manifestations. Although DM primarily affects skin and muscle, the disease can cause pathologic changes to other organs such as the lungs, and may be associated with malignancy. Various treatments are deployed in DM management, but their effects are inconsistent. Skin disease can be refractory to therapy, even when other involved organ systems are responsive.1 Interferons (IFNs) are believed to play a role in driving DM disease activity, and medications targeting IFN pathways are both available and under development.